-

Effects, Lessons of Pandemic Focus of Stanford Symposium Series Featuring Distinguished Speakers

PALO ALTO, Calif.--(BUSINESS WIRE)--The COVID-19 pandemic has killed millions, threatened the health of billions and disrupted every aspect of society. And while its impact will be felt for decades, COVID-19 won’t be the last global threat of its kind. What we do to prepare for the next one is critical.

That reality is the motivation for an ambitious symposium series presented by Stanford Medicine and the Stanford Graduate School of Business that will convene eminent experts — across health care, business and government — to discuss the global COVID-19 response, lessons for recovery and how we can better prepare for future threats.

By capturing a wealth of perspectives and spotlighting innovative thinking, The Pandemic Puzzle: Lessons from COVID-19 series will help define how different sectors might rebuild to emerge stronger and more resilient.

The virtual, interactive, multi-day symposium is free and open to the public.

“We have a once-in-generations opportunity — and a profound responsibility — to learn from this crisis and recreate a health system that is more responsive, efficient and equitable,” said Lloyd Minor, MD, the Carl and Elizabeth Naumann Professor and dean of the Stanford School of Medicine. “This conference will be an important step toward making that happen.”

Jonathan Levin, PhD, Philip H. Knight Professor and dean of Stanford Graduate School of Business, who is co-hosting the conference with Minor, said that the next few years will be critical. “We must seize the moment and the momentum,” he said. “The pandemic disrupted the health system and our entire economy, revealing weaknesses and disparities. We can use that information and insight to build a stronger foundation and a brighter future.”

Conference attendees will hear the latest thinking from leading epidemiologists and public health officials, business leaders in vaccination development and delivery, and the policymakers who were on the front lines of the global response. Speakers include Janet Woodcock, MD, acting commissioner of the U.S. Food and Drug Administration; Andy Slavitt, a former senior adviser from President Joe Biden’s COVID-19 response team; Sally Susman, chief corporate affairs officer at Pfizer; Soumya Swaminathan, chief scientist at the World Health Organization; renowned economist Alex Tabarrok, PhD; and Marcella Nunez-Smith, MD, MHS, chair of the White House’s COVID-19 Health Equity Task Force.

Joined by leading faculty from the Stanford School of Medicine and Stanford Graduate School of Business, the conference will cover multiple aspects of the pandemic and the global response. Panelists and session participants will explore the intersecting roles of government, industry, health care and academia; the pandemic’s impact on American households and the global economy; underlying issues of access, equity and community health and their importance in improving a future pandemic response; the need to modernize critical elements of our global health systems; the pandemic’s knock-on effects and their impact on education and housing; and the potential of cutting-edge technologies and biomedical research to blunt or even prevent future pandemics.

Registration is open. To see a detailed agenda, the latest speakers and to register, visit the website.

About Stanford University School of Medicine

The Stanford University School of Medicine consistently ranks among the nation’s top medical schools, integrating research, medical education, patient care and community service. For more news about the school, please visit http://med.stanford.edu/school.html. The medical school is part of Stanford Medicine, which includes Stanford Health Care and Stanford Children’s Health. For information about all three, please visit http://med.stanford.edu.

About Stanford Graduate School of Business

Stanford Graduate School of Business (GSB) is developing the next generation of principled global leaders. Since 1925, Stanford GSB has been delivering rigorous and experiential management education combined with personal development and leadership that has the power to change both careers and lives. Stanford GSB’s faculty are empowered to design and discover original research that pushes the boundaries of knowledge. The school’s diverse programs include the 2-year MBA program; 1-year Master of Science program for experienced leaders (MSx); PhD program; Executive Education; Stanford LEAD, an online certificate program; and Stanford Seed, a Stanford GSB-led initiative that partners with entrepreneurs in emerging markets to build thriving enterprises that transform lives.

Contacts

Courtney Lodato
(650) 213-2217
clodato@stanfordhealthcare.org

Stanford Medicine


Release Summary
Stanford Medicine and Stanford Graduate School of Business Present the Pandemic Puzzle: Lessons from COVID-19
Release Versions

Contacts

Courtney Lodato
(650) 213-2217
clodato@stanfordhealthcare.org

More News From Stanford Medicine

Stanford Medicine to Launch the Patients Like MineSM Suite of Services, Empowering Community Physicians with Data and Reference Solutions

STANFORD, Calif.--(BUSINESS WIRE)--Stanford Medicine is launching the Patients Like MineSM, suite of services specifically designed to equip community physicians in diverse practice settings with the data and reference solutions to assist them in delivering evidence-based, high-quality care to their patients. Patients Like MineSM services will enable community physicians to leverage Stanford Medicine’s digital tools, large language models and artificial intelligence-enabled services while prese...

Stanford Medicine and Northpond Ventures Announce the Launch of The Northpond Laboratories - Program for Research and Innovation at Stanford Medicine

STANFORD, Calif.--(BUSINESS WIRE)--Stanford Medicine and Northpond Ventures announced the launch of The Northpond Laboratories - Program for Research and Innovation at Stanford Medicine. The program seeks to identify and build upon the scientific discoveries and innovations developed by Stanford Medicine's leading faculty and researchers and accelerate the pace of translation between scientific research to clinical and commercial applications that improve patient outcomes through the vehicle of...

Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories (Intonation) form a collaboration to fight cancerous neuroendocrine tumors

STANFORD, Calif.--(BUSINESS WIRE)--Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells. The goal of the collaboration is to reduce the time and resources it takes to translate a biomedical breakthrough into a clinically and commercially viable medicine. “I’m excited about this collaboration with...
Back to Newsroom